Review
Open access
Aug 2026
GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control
Current evidence supports use of agents with demonstrated benefit within layered therapy that also includes renin-angiotensin system blockade, sodium-glucose cotransporter 2 inhibition, and, when indicated, finerenone, which requires gradual dose escalation, attention to gastrointestinal intolerance and volume depletio...
Marcella Culau Vieira, V. Cunha, Rodrigo Gonçalves Corrêa et al.
· International Health Science... · 0 citations